ENDRA Life Sciences

ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ENDRA Life Sciences reports Q1 loss, eyes market expansion

ENDRA Life Sciences is navigating challenges in a competitive market while leveraging its strengths in innovation and strategic partnerships. The company's performance in Q1 2024 reflects progress in clinical research and regulatory alignment for its TAEUS system.

ENDRA Life Sciences charts strategic course for growth and innovation

ENDRA Life Sciences is making strategic changes to drive future growth and innovation. With a focus on regulatory alignment, clinical trials, and business strategy refinement, the company aims to enhance its market position. Despite financial challenges, ENDRA remains optimistic about its future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today reported the closing of its previously announced underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per share. In connection with the offering, the underwriter exercised its over-allotment option to purchase an additional 714,286 shares of common stock at the public offering price, less the underwriting discount, in full.

ENDRA Life Sciences Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q3 2020 Results - Earnings Call Transcript

ENDRA Life Sciences Inc.'s (NDRA) CEO Francois Michelon on Q2 2020 Results - Earnings Call Transcript

TAEUS device fills the need for a non-invasive test for NASH.

ENDRA Life Sciences' NASH Test Device, TAEUS, At Commercialization Inflection Point

ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q1 2020 Results - Earnings Call Transcript

ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q4 2019 Results - Earnings Call Transcript

ENDRA Life Sciences, Inc. (NDRA) CEO Francois Michelon on Q3 2019 Results - Earnings Call Transcript

ENDRA Life Sciences' (NDRA) CEO Francois Michelon on Q2 2019 Results - Earnings Call Transcript

ENDRA released data at the end of 2019Q1 that didn't live up to the market's expectation, sending its share price down to new lows.

ENDRA Is A Great Investment Opportunity, With A Bit Of Finesse

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q1 2019 Results - Earnings Call Transcript

News for ENDRA Life Sciences Stock (NDRA)